Advertisement
To access the conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international). A replay of the call will be available from 11:00p.m. ET on November 18 until December 2, 2008. To access the replay, pleasedial 1-877-660-6853 (USA) or 1-201-612-7415 (international) and reference theaccount number 3055 and the access code 303493.
Advertisement
A live audio webcast of the call will also be available from the Investorssection on the corporate web site at http://www.sinovac.com . A webcast replaycan be accessed on the corporate website beginning November 18, 2008 and thereplay will remain available for 30 days.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company thatfocuses on the research, development, manufacture and commercialization ofvaccines that protect against human infectious diseases. Sinovac'scommercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combinedhepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac iscurrently developing Universal Pandemic Influenza vaccine and Japaneseencephalitis vaccine. Additional information about Sinovac is available on itswebsite, http://www.sinovac.com . To be added to our distribution list, pleaseemail: [email protected] .For more information, please contact: Helen G. Yang Sinovac Biotech Ltd. Phone: +86-10-8289-0088 x871 Fax: +86-10-6296-6910 Email: [email protected] Investors/Media: Stephanie Carrington/Janine McCargo The Ruth Group Tel: +1-646-536-7017/7033 Email: [email protected] [email protected]
SOURCE Sinovac Biotech Ltd.
